Table 3. Total cases, rates, and male to female incidence rate ratios, by age group and histologic type (2000–2017).
| Males and Females | Males | Females | Male/Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Count | % of
total |
Count | % of
total |
Rate | Count | % of
total |
Rate | IRR | LCI | UCI | |
| Total cases | 152548 | 100 | 79081 | 51.84 | 19.4 | 73467 | 48.15 | 14.7 | 1.32 | 1.30 | 1.33 |
| Age groups | |||||||||||
| 30–34 years | 543 | 0.35 | 243 | 0.3 | 0.5 | 300 | 0.4 | 0.6 | 0.8 | 0.67 | 0.95 |
| 35–39 years | 1,197 | 0.78 | 646 | 0.8 | 1.2 | 551 | 0.7 | 1 | 1.2 | 1.04 | 1.31 |
| 40–44 years | 2,651 | 1.7 | 1,458 | 1.8 | 2.7 | 1,193 | 1.6 | 2.2 | 1.2 | 1.14 | 1.33 |
| 45–49 years | 5,668 | 3.7 | 3,182 | 4.0 | 5.9 | 2,486 | 3.3 | 4.5 | 1.3 | 1.24 | 1.38 |
| 50–54 years | 10,364 | 6.7 | 6,041 | 7.6 | 11.9 | 4,323 | 5.8 | 8.2 | 1.5 | 1.39 | 1.50 |
| 55–59 years | 15,815 | 10.3 | 9,025 | 11.4 | 20.4 | 6,790 | 9.2 | 14.5 | 1.4 | 1.37 | 1.45 |
| 60–64 years | 20,378 | 13.3 | 11,465 | 14.49 | 32.5 | 8,913 | 12.1 | 23.1 | 1.4 | 1.37 | 1.44 |
| 65–69 years | 23,226 | 15.2 | 12,645 | 15.98 | 46.8 | 10,581 | 14.4 | 34.4 | 1.4 | 1.32 | 1.39 |
| 70–74 years | 23,319 | 15.2 | 12,082 | 15.27 | 60 | 11,237 | 15.3 | 46.1 | 1.3 | 1.27 | 1.34 |
| 75–79 years | 21,789 | 14.2 | 10,418 | 13.17 | 69.4 | 11,371 | 15.5 | 56.9 | 1.2 | 1.19 | 1.25 |
| 80–84 years | 16,467 | 10.7 | 7,476 | 9.4 | 72.5 | 8,991 | 12.2 | 57.4 | 1.3 | 1.23 | 1.30 |
| 85+ years | 11,131 | 7.2 | 4,400 | 5.5 | 53.8 | 6,731 | 9.1 | 40.5 | 1.3 | 1.28 | 1.38 |
| Histological type | |||||||||||
| Total | 139267 | 100 | 72097 | 51.76 | 17.6 | 67170 | 48.23 | 13.5 | 1.31 | 1.29 | 1.32 |
| Adenocarcinoma, not otherwise specified | 104,926 | 75.3 | 54344 | 75.4 | 13.3 | 50582 | 75.3 | 10.1 | 1.3 | 1.30 | 1.34 |
| Ductal adenocarcinoma excluding cystic
or mucinous |
17,026 | 12.2 | 8658 | 12 | 2.1 | 8368 | 12.5 | 1.7 | 1.25 | 1.21 | 1.3 |
| Cystic adenocarcinoma | 408 | 0.2 | 118 | 0.1 | 0.0 | 290 | 0.4 | 0.1 | 0.5 | 0.4 | 0.6 |
| Ductal specified as arising from an
intraductal papillary mucinous neoplasm |
520 | 0.3 | 268 | 0.3 | 0.1 | 258 | 0.3 | 0.1 | 1.3 | 1.1 | 1.5 |
| Endocrine: non-secretory | 6,167 | 4.4 | 3484 | 4.8 | 0.8 | 2683 | 3.9 | 0.6 | 1.5 | 1.4 | 1.6 |
| Secretory endocrine | 203 | 0.1 | 94 | 0.1 | 0.0 | 109 | 0.1 | 0.0 | 0.9 | 0.9 | 1.3 |
| Carcinoid tumors | 3,201 | 2.2 | 1753 | 2.4 | 0.4 | 1448 | 2.1 | 0.3 | 1.4 | 1.3 | 1.5 |
| Acinar cell adenocarcinomas | 438 | 0.3 | 314 | 0.4 | 0.1 | 124 | 0.2 | 0.0 | 3.0 | 2.5 | 3.8 |
| Mucinous adenocarcinoma | 5,696 | 4.1 | 2790 | 3.9 | 0.7 | 2906 | 4.3 | 0.6 | 1.2 | 1.1 | 1.2 |
| Solid pseudopapillary tumors | 228 | 0.2 | 42 | 0.05 | 0.0 | 186 | 0.3 | 0.0 | 0.2 | 0.2 | 0.3 |
| Other adenocarcinoma | 448 | 0.3 | 229 | 0.3 | 0.1 | 219 | 0.3 | 0.1 | 1.3 | 1.1 | 1.5 |
| Other non-carcinomas | 6 | 0.004 | 3 | 0.004 | 0.0 | 3 | 0.004 | 0.0 | 0.9 | 0.1 | 7.7 |
Rates are per 100 000 person-years, age-adjusted to the 2000 US Standard Population (19 age groups - Census P25–1130).
IRR = Incidence Rate Ratios (based on unrounded rates); LCI, UCI = lower, upper 95% confidence interval.
Confidence intervals (Tiwari mod) are 95% for the ratios.